NCT02951195 A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis Status COMPLETED Phase PHASE2
NCT02951182 A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis Status COMPLETED Phase PHASE2
NCT02934698 An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations Status COMPLETED Phase PHASE3
NCT02875366 A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation Status COMPLETED Phase PHASE4
NCT02871778 Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia Status COMPLETED Phase PHASE2
NCT02823470 A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation Status TERMINATED Phase PHASE4
NCT02797132 Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del Status COMPLETED Phase PHASE3
NCT02742519 A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation Status TERMINATED Phase PHASE3
NCT02730208 A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation Status COMPLETED Phase PHASE2
NCT02725567 A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation Status COMPLETED Phase PHASE3
NCT02722057 A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients Status COMPLETED Phase N/A
NCT02709109 A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Status COMPLETED Phase PHASE2
NCT02669849 Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury Status TERMINATED Phase PHASE2/PHASE3
NCT02660424 A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee Status COMPLETED Phase PHASE2
NCT02565914 A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation Status COMPLETED Phase PHASE3
NCT02544451 Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor Status COMPLETED Phase PHASE3
NCT02516410 A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation Status COMPLETED Phase PHASE3
NCT02514473 A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation Status COMPLETED Phase PHASE3
NCT02508207 A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Status COMPLETED Phase PHASE2
NCT02445053 Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) Status COMPLETED Phase N/A